【家庭护理】严防足部皮肤破损！糖尿病患者护脚指南

首页
病情图文
- 糖尿病足
- 压疮
- 感染伤口
- 造口
- 溃疡
  
  动脉性溃疡
  
  静脉性溃疡
  
  放射性溃疡
- 烧伤
- 创伤
- 少见伤口
- 祛疤止痒
- 皮肤病
医师讲座
名医介绍
专业服务

糖尿病足

压疮

造口

溃疡

烧伤
蔡道章院长

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长

中德骨科伤口管理学校校长

广东省骨科研究院运动医学研究所所长

广东省内运动医学专业唯一的博士研究生导师

美国哈弗大学医学院骨科访问学者

专业特长处于省内领先、国内或国际先进水平以上

2018年获得“国之名医卓越建树”荣誉称号

2017年被评为全国卫生计生系统先进工作者、广东省医学领军人才

中国医师协会运动医师分会副会长

STCOT中国部运动医学分会副主任委员

广东省医学会关节外科分会主任委员

广东省医学会运动医学会分会名誉主任委员

独立承担过国家“863”课题，主持过10余项省、部级科研项目

多份专业杂志编委
文献精选
伤口分类

糖尿病足

压疮

感染伤口

造口

溃疡

烧伤

更多关于伤口信息
最新文献

The role of fecal microbiota transplantation in diabetes 2026-05-22 00:00

Gabriele Angelo Vassallo1 · Tommaso Dionisi2,3 · Vittorio De Vita4 · Giuseppe Augello1 ·Antonio Gasbarrini3,5 · Dario Pitocco6 · Giovanni Addolorato2,3

Received: 25 January 2025 / Accepted: 29 March 2025 / Published online: 19 April 2025 © The Author(s) 2025

Abstract

Fecal microbiota transplantation (FMT) has emerged as a potential therapeutic strategy for modulating gut dysbiosis in diabetes mellitus. This review critically evaluates preclinical and clinical evidence on FMT in type 1 (T1D) and type 2 dia-betes (T2D). Studies suggest that FMT can restore microbial diversity, improve glycemic control, and modulate immune responses, with varying effects across diabetes subtypes. In T1D, preclinical models demonstrate that FMT influences regulatory T-cell expansion and β-cell preservation, though clinical translation remains limited. In T2D, FMT has shown transient improvements in insulin sensitivity, with sustained effects observed only in patients with specific microbiome signatures. However, heterogeneity in patient responses, donor variability, and methodological limitations complicate its clinical application. This review highlights the interplay between FMT, immune modulation, and microbial metabolism, advocating for phenotype-stratified trials and multi-omics integration to enhance therapeutic precision.

Keywords Fecal microbiota transplantation · Intestinal Microbiome · Diabetes · Insulin sensitivity · Metabolic syndrome · Beta-cell

Abbreviations

FMT Fecal microbiota transplantation TUDCA Tauroursodeoxycholic acid VEGF Vascular endothelial growth factor SCFAs Short-chain fatty acids MMTT Mixed meal tolerance test FVT Fecal virome transplantation OGTT Oral glucose tolerance test SRB Sulfate-reducing bacteria LSI Lifestyle intervention

Relationship between liver fat, pancreatic fat, and new-onset type 2 diabetes mellitus in patients with metabolic dysfunction-associated fatty liver disease 2026-05-21 00:00

Huanjia Qu1 · Lingling Zhou1 · Dong Tang2 · Qiuling Zhang1 · Pu Yang3 · Boyi Yang3 · Junping Shi4

Received: 25 December 2024 / Accepted: 22 March 2025 / Published online: 19 April 2025 © The Author(s) 2025

Abstract

Purpose Type 2 diabetes mellitus (T2DM) is associated with ectopic fat deposition, especially in the liver and pancreas.Therefore, this study aimed to evaluate the relationship between liver fat fraction (LFF), pancreatic fat fraction (PFF), and new-onset T2DM in metabolic dysfunction-associated fatty liver disease (MAFLD) by magnetic resonance imaging (MRI).

Methods This is a retrospective study of patients with MAFLD who underwent abdominal MRI between 2022 and July 2024. LFF and PFF were measured using an axial multi-echo Dixon-based sequence. All participants underwent routine medical history, anthropometric measurements, and laboratory tests. Multivariable stepwise selection models were con-structed to predict PFF and T2DM status based on variables of clinical interest.

Results This study included 80 MAFLD patients with 40 untreated new-onset T2DM and 40 non-T2DM controls. LFF, PFF, and homeostasis model assessment of insulin resistance (HOMA-IR) index were higher in the T2DM group than in the control group. In the new-onset T2DM group, PFF was linearly positively correlated with LFF (rs=0.321, P=0.04) and HOMA-IR (rs=0.350, P=0.03). After adjustment for several metabolic variables, PFF remained an independent risk factor for incident T2DM in MAFLD patients (all P<0.05). The area under the receiver operating characteristic curve for PFF and LFF to predict T2DM was 0.889 and 0.633 (P<0.001 and P=0.03), respectively.

Conclusion In MAFLD patients, PFF, and LFF play a prominent role in new-onset T2DM with high predictive and diag-nostic value.

Keywords Metabolic dysfunction-associated fatty liver disease · Type 2 diabetes mellitus · Liver fat fraction ·Pancreatic fat fraction · Ectopic fat deposition · MRI
互动快递

【家庭护理】严防足部皮肤破损！糖尿病患者护脚指南

字号 + –

06 9月 2019

Author : 伤口世界

中诺医疗文章转载公众号上海第九人民医院作者谢挺

糖尿病患者大约有1.5%会发生足部溃疡，足部溃疡经久不愈，继发感染，发生坏疽。糖尿病足的截肢率很高，有报道称截肢率可高达85%，给患者造成极大痛苦，而通过积极的预防措施，可以降低40%~80%的截肢发生率。

　　在糖尿病足的预防和综合治疗中，足部护理占有特别突出的地位，通过家庭中实施的足部护理，可有效地防止或延缓糖尿病足的发生发展。足部护理的主要内容包括以下方面：

　　注意局部皮肤变化，观察皮肤的色、温度及感觉。如皮肤干燥无汗、弹性差、毛发脱落、皮温下降、皮色变暗、足背动脉搏动减弱或消失，提示动脉供血不足；如皮肤感觉缺失提示有神经营养障碍。

　　注意足部的保护，鞋袜要合适，最好选用软底布鞋及棉线袜，穿着以舒适不挤脚为宜，以保证足部血液循环的供应。由于糖尿病患者末梢神经感觉障碍，对冷热等物理刺激反应迟钝，因此冬天注意足部保暖，避免冻伤，用热水袋取暖时，热水袋内水温不超过60℃，热水袋外面用毛巾套包裹，不可直接触及皮肤，以防烫伤。

　　注意足部卫生，每晚用40~42℃的温水浸泡双脚15~30分钟，洗后用柔软吸水性强的毛巾擦干。消除过厚角质层防止干裂，可涂上植物油按摩，以保持皮肤柔软。

　　按摩足部以改善微循环。足部按摩每日早、中、晚各一次，每次10分钟，动作轻柔，应从趾尖开始向上按摩，有利于循环流畅。

　　修剪趾甲不应太靠近皮肤以免损伤甲沟皮肤导致感染，应沿着足趾甲平行修剪，不要剪向趾甲边角的深部。有胼胝的患者不要自行处理，应请专业人员帮助处理，避免不适当地应用鸡眼膏或脚癣浸泡液，以免造成足部感染。

　　减轻病变部位的负重。为了减轻病变局部的压迫，患者应注意卧床休息，不可长时间站立，行走时使用拐杖。患肢水肿者，把患肢抬高18~30°以利于静脉回流，减轻水肿。

　　日常多进行腿部运动，每日适当步行，做到定时、定量、量力而行、持之以恒。对较轻的患者可在护士的指导下，手扶椅子做单腿站立或甩腿运动，不能行走的患者在床上取坐姿位做提足运动，每日1~2次，每次至少20下。

　　糖尿病患者足部皮肤常易发生水疱，皮肤水疱易诱发感染和坏疽，一旦出现要积极处理。保持水疱清洁，避免受压，微循环改善后可自行吸收；对严重的水疱，可在无菌操作下抽出渗液。医生建议，出现了类似水疱等糖尿病皮肤早期皮肤损害，应当前往医院，在专业医护人员的指导下进行处理。

文章作者创面修复科谢挺副主任医师

1842 Views

伤口世界

电子邮件地址该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Latest from 伤口世界

K2 Content

The role of fecal microbiota transplantation in diabetes 2026-05-22 00:00

Gabriele Angelo Vassallo1 · Tommaso Dionisi2,3 · Vittorio De Vita4 · Giuseppe Augello1 ·Antonio Gasbarrini3,5 · Dario Pitocco6 · Giovanni Addolorato2,3

Received: 25 January 2025 / Accepted: 29 March 2025 / Published online: 19 April 2025 © The Author(s) 2025

Abstract

Fecal microbiota transplantation (FMT) has emerged as a potential therapeutic strategy for modulating gut dysbiosis in diabetes mellitus. This review critically evaluates preclinical and clinical evidence on FMT in type 1 (T1D) and type 2 dia-betes (T2D). Studies suggest that FMT can restore microbial diversity, improve glycemic control, and modulate immune responses, with varying effects across diabetes subtypes. In T1D, preclinical models demonstrate that FMT influences regulatory T-cell expansion and β-cell preservation, though clinical translation remains limited. In T2D, FMT has shown transient improvements in insulin sensitivity, with sustained effects observed only in patients with specific microbiome signatures. However, heterogeneity in patient responses, donor variability, and methodological limitations complicate its clinical application. This review highlights the interplay between FMT, immune modulation, and microbial metabolism, advocating for phenotype-stratified trials and multi-omics integration to enhance therapeutic precision.

Keywords Fecal microbiota transplantation · Intestinal Microbiome · Diabetes · Insulin sensitivity · Metabolic syndrome · Beta-cell

Abbreviations

FMT Fecal microbiota transplantation TUDCA Tauroursodeoxycholic acid VEGF Vascular endothelial growth factor SCFAs Short-chain fatty acids MMTT Mixed meal tolerance test FVT Fecal virome transplantation OGTT Oral glucose tolerance test SRB Sulfate-reducing bacteria LSI Lifestyle intervention
Relationship between liver fat, pancreatic fat, and new-onset type 2 diabetes mellitus in patients with metabolic dysfunction-associated fatty liver disease 2026-05-21 00:00

Huanjia Qu1 · Lingling Zhou1 · Dong Tang2 · Qiuling Zhang1 · Pu Yang3 · Boyi Yang3 · Junping Shi4

Received: 25 December 2024 / Accepted: 22 March 2025 / Published online: 19 April 2025 © The Author(s) 2025

Abstract

Purpose Type 2 diabetes mellitus (T2DM) is associated with ectopic fat deposition, especially in the liver and pancreas.Therefore, this study aimed to evaluate the relationship between liver fat fraction (LFF), pancreatic fat fraction (PFF), and new-onset T2DM in metabolic dysfunction-associated fatty liver disease (MAFLD) by magnetic resonance imaging (MRI).

Methods This is a retrospective study of patients with MAFLD who underwent abdominal MRI between 2022 and July 2024. LFF and PFF were measured using an axial multi-echo Dixon-based sequence. All participants underwent routine medical history, anthropometric measurements, and laboratory tests. Multivariable stepwise selection models were con-structed to predict PFF and T2DM status based on variables of clinical interest.

Results This study included 80 MAFLD patients with 40 untreated new-onset T2DM and 40 non-T2DM controls. LFF, PFF, and homeostasis model assessment of insulin resistance (HOMA-IR) index were higher in the T2DM group than in the control group. In the new-onset T2DM group, PFF was linearly positively correlated with LFF (rs=0.321, P=0.04) and HOMA-IR (rs=0.350, P=0.03). After adjustment for several metabolic variables, PFF remained an independent risk factor for incident T2DM in MAFLD patients (all P<0.05). The area under the receiver operating characteristic curve for PFF and LFF to predict T2DM was 0.889 and 0.633 (P<0.001 and P=0.03), respectively.

Conclusion In MAFLD patients, PFF, and LFF play a prominent role in new-onset T2DM with high predictive and diag-nostic value.

Keywords Metabolic dysfunction-associated fatty liver disease · Type 2 diabetes mellitus · Liver fat fraction ·Pancreatic fat fraction · Ectopic fat deposition · MRI
Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland 2026-05-20 00:00

Krzysztof Łupina1 · Artur Dziewierz2,3 · Jakub Janczura1 · Zbigniew Siudak1,4

Received: 6 March 2026 / Accepted: 26 April 2026

© The Author(s) 2026

Abstract

Aims To characterize switching among GLP-1 receptor agonists (GLP-1 RAs) in a large private-sector cohort in Poland and to quantify therapy- and patient-level associations with switching while accounting for switching opportunity and calendar-time dynamics.

Methods We conducted a retrospective analysis of GLP-1 RA prescription records from the LUX MED network (2018–2025). Switching was defined as any change in agent between consecutive prescriptions. Patients with more than one pre-scription were included (n=42,423). The primary analysis used a transition-level discrete-time hazard model in which each prescription-to-prescription interval contributed one observation, and the outcome was switching at that interval. Current-therapy contrasts were reported relative to subcutaneous semaglutide. Sensitivity analyses examined alternative temporal parameterizations and additional adjustment for elapsed time.

Results Overall, 29.7% of patients switched at least once and 14.3% switched two or more times. In the transition-level analysis, 12,620 patients contributed 27,095 transitions. After adjustment for opportunity and calendar time, liraglutide was associated with substantially lower odds of switching compared with subcutaneous semaglutide (OR, 0.02; 95% CI, 0.01–0.03), whereas oral semaglutide (OR, 1.30; 95% CI, 0.78–2.17) and dulaglutide (OR, 1.70; 95% CI, 0.95–3.04) did not differ significantly. Temporal analyses revealed peaks consistent with episodic substitution and accelerated tirzepatide uptake after market entry. The principal associations remained directionally consistent in sensitivity analyses.

Conclusions Switching among GLP-1 RAs is common and time-dependent. Time-aware modelling identified therapy-spe-cific switching patterns and pronounced temporal variation; reasons for switching remain unmeasured, and the observed associations should be interpreted as hypothesis-generating.

Keywords Glucagon-like peptide-1 receptor agonists · Tirzepatide · Treatment switching · Real-world evidence · Private healthcare · Obesity

Popular Tags

学术会议

2019广东省医疗行业协会伤口管理分会年会

扫一扫了解详情:

2019年6月15日中国广州
主办单位：广东省医疗行业协会伤口管理分会

伤口世界提示

任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考，最终以医院当日公布为准。

网友、医生言论仅代表其个人观点，不代表本站同意其说法，请谨慎参阅，本站不承担由此引起的法律责任。

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长